本帖最后由 老马 于 2012-1-13 21:20 编辑
" q B# A X8 E( q" b, ?# @: U4 G0 v' y k
爱必妥和阿瓦斯丁的比较, y8 M# P6 k5 M
4 Y( ~2 `! V6 J) P" D# j" ]
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
- ]5 d& F3 J* f# s5 z
" Z1 Z+ M! l+ p% p
2 d% v- H* d. y4 w, l Q) zhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
% h) m& s% E: V0 p==================================================
5 O- F p3 f2 H/ IOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 w! \6 \0 l6 ^Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point./ ~1 M+ r) c5 o- }
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.) T+ u7 L3 B; e. C+ b0 h
|